**Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis**

**AUTHORS**

Danielle E. Robinson\*,1, M Sanni Ali\*,1-3, Natalia Pallares4, Cristian Tebé4,5, Leena Elhussein1, Bo Abrahamsen6-8, Nigel K. Arden9, Yoav Ben-Shlomo10, Fergus J Caskey10,11, Cyrus Cooper6,12, Daniel Dedman13, Antonella Delmestri1, Andrew Judge1,12,14, María José Pérez-Sáez15, Julio Pascual15, Xavier Nogues16,17, Adolfo Diez-Perez16, Victoria Y. Strauss¶,1, M. Kassim Javaid\*\*,6, Daniel Prieto-Alhambra\*\*,1,18

\* Joint first authors

\*\* Joint senior authors

**AFFILIATIONS**

1. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Windmill Road, University of Oxford, Oxford, UK
2. Faculty of Epidemiology and Population Health, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
3. Department of Public Health, Saint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
4. Biostatistics Unit, Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet de Llobregat, 08907 Barcelona, Spain
5. Basic Medical Sciences Department, Rovira Virgili University, Reus, Tarragona, Spain
6. NDORMS, Windmill Road, University of Oxford, Oxford, UK
7. OPEN, Department of Health, University of Southern Denmark, Odense, Denmark.
8. Holbæk Hospital, Dept of Medicine, Holbæk, Denmark
9. Sport, Exercise and Arthritis Centre: versus arthritis, University of Oxford, Oxford UK
10. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
11. North Bristol NHS Trust, Bristol. BS10 5NB
12. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
13. Clinical Practice Research Datalink (CPRD), London, UK
14. Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
15. Department of Nephrology, Hospital del Mar, Barcelona, Spain
16. Internal Medicine. IMIM (Hospital del Mar Research Institute), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Barcelona, Spain.
17. Hospital del Mar Institute of Medical Research Autonomous University of Barcelona Research Network on Frailty and Healthy Aging (CIBERFES) Instituto Carlos III, Barcelona, Spain
18. Grup de Recerca en Malalties Prevalents de l’Aparell Locomotor (GREMPAL) Research Group and CIBERFes, University Institute for Primary Care Research (IDIAP) Jordi Gol, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.

**¶ CORRESPONENCE TO**

Dr Victoria Strauss

Pharmaco- and Device Epidemiology, CSM, NDORMS

Botnar Research Centre

OX37LD, Oxford, United Kingdom

Email: Victoria.strauss@csm.ox.ac.uk

Tel: 01865 223 721

**COMPETING INTERESTS**

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare: DPA reports grants and other from AMGEN; grants, non-financial support, and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work. DPA also reports that Janssen, on behalf of the IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes that are organised by DPA's department and are open to external participants. AJ reports personal fees from Freshfields Bruckhaus Derringer and Anthera Pharmaceuticals INC, outside the submitted work. CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. KJ reports grants from NIHR HTA during the conduct of the study and personal fees from UCB and AMGEN, outside the submitted work. NA reports grants from Merck and personal fees from Merck, Regeneron, Pfizer/Lilly, and Flexion, outside the submitted work. VS reports consultancy fees from Janssen Pharmaceutica NV, during the conduct of the study. XN reports advisory boards for Amgen, Lilly, and Formation, and talks for Amgen, Lilly, FAES, and ITALFARMACO. ADP reports personal fees from AMGEN-UCB, Lilly, Gilead, and Sandoz; other from Active Life Sci; and personal fees and non-financial support from EchoLight, outside the submitted work. BA reports institutional research contracts and personal consulting fees from UCB Biopharma sprl, institutional research contracts from Novartis, personal speaker’s fees from Eli Lily and Amgen, and personal consulting fees from Kyowa-Kirin Plc. CT reports personal fees from Boehringer Ingelheim and Amgen, outside the submitted work.

**DATA ACCESS STATEMENT**

Data were obtained from CPRD under the Oxford University CPRD license and ISAC approval and SIDIAP by IDIBELL. Direct data sharing is not allowed. Data access can be obtained from CPRD, conditional on ISAC approval and SIDIAP after protocol approval.

**ABSTRACT**

Bisphosphonates are the first-line treatment for preventing fractures in osteoporosis patients. However, their use is contraindicated or to be used with caution in chronic kidney disease (CKD) patients, primarily due to a lack of information about their safety and effectiveness. We aimed to investigate the safety of oral bisphosphonates in patients with moderate-to-severe CKD. Using primary-care electronic records from two cohorts, CPRD GOLD (1997-2016) and SIDIAP (2007-2015) in the UK and Catalonia, respectively. Both databases were linked to hospital records. SIDIAP was also linked to end-stage renal disease registry data. Patients with CKD stage 3b-5, based on 2 or more estimated glomerular filtration rate measurements less than 45 ml/min/1.73m2, aged 40 years or older were identified. New bisphosphonate users were propensity-score-matched with up to five non-users to minimise confounding within this population. Our primary outcome was CKD stage worsening (eGFR decline or renal replacement therapy). Secondary outcomes were acute kidney injury, gastrointestinal bleeding/ulcers, and severe hypocalcaemia. Hazard ratios (HRs) were estimated using Cox regression and Fine and Gray sub-HRs were calculated for competing risks. We matched 2,447 bisphosphonate users with 8,931 non-users from CPRD and 1,399 users with 6,547 non-users from SIDIAP. Bisphosphonate use was associated with greater risk of CKD progression in CPRD (HR [95% CI]: 1.14 [1.04, 1.26]) and SIDIAP (HR: 1.15 [1.04, 1.27]). No risk differences were found for acute kidney injury, gastrointestinal bleeding/ulcers, or hypocalcaemia. Hence, we can conclude a modest (15%) increased risk of CKD progression was identified in association with bisphosphonate use. No other safety concerns were identified. Our findings should be considered before prescribing bisphosphonates to patients with moderate-to-severe CKD.

**Key words**

General population studies, Antiresorptives, Statistical methods, Osteoporosis, Fracture prevention,

**INTRODUCTION**

Moderate-to-severe (stage 3-5) chronic kidney disease (CKD) affects up to 2.8 million people in the United Kingdom (UK)[1] and 2.7 million people in Spain[2]. CKD is associated with low bone mass[3]. Increased fracture risk is associated with increasing CKD severity [4] [5] [6, 7].

Although bisphosphonates are first-line anti-osteoporosis therapies for preventing fractures, their use is contraindicated or to be used with caution in patients with an estimated glomerular filtration rate (eGFR) under 30 ml/min/1.73m2. Clinical guidelines[8-10] and drug regulators[11-13] impose similar restrictions.

A systematic review of the benefits and harms of anti-osteoporosis medications, including bisphosphonates, suggested that bisphosphonates did not increase the risk of renal adverse events (373 patients from 4 trials), gastrointestinal events (179 patients from 2 trials), or hypocalcaemia (93 patients from 1 trial)[14]. The review acknowledged that most of the included studies had possible reporting bias and that the results might not apply to patients with stage 3b-5 CKD due to scant evidence in this population. Reporting bias was driven by selective reporting of trial outcomes, unclear methods, and restricted study designs (randomised trials with 6-36 months follow-up). The participants in the included trials were also far healthier than bisphosphonate users in actual practice settings.

The most recent (2017) Kidney Disease Outcomes Quality Initiative guidelines[15] proposed that potential kidney progression, the severity of any biochemical abnormalities, fracture risk, and bone and mineral disorders related to CKD should be considered when deciding whether to prescribe bisphosphonates. There is an urgent need for data on the risks and benefits of bisphosphonates for patients with moderate-to-severe CKD.

Following a commissioned call from the UK National Institute for Health Research, we analysed routinely collected data from Spain and the UK to establish the safety of bisphosphonates in patients with stage 3b-5 CKD. Our pre-specified list of safety events included CKD worsening (primary outcome), acute kidney injury, gastrointestinal events, and severe hypocalcaemia (secondary outcomes).

**METHODS**

**Data sources**

This study used a cohort design with data from two primary-care electronic health record databases linked to hospital records.

We used 1997-2016 records from the UK’s Clinical Practice Research Datalink (CPRD) GOLD linked with Hospital Episode Statistics (HES). CPRD-HES contains anonymised primary- and secondary-care records from 401 English primary-care practices (58% of CPRD-registered practices). In CPRD, practices suitable for research purposes are considered “up to standard”[16].

We also used 2007-2015 records from Catalonia’s Information System for the Development of Research in Primary Care (SIDIAP) linked with the National Hospital Discharge Database and renal registry. SIDIAP contains information on 5.8 million patients from 279 practices in the Catalonia region of Spain, representing 80% of that population[17].

Both datasets are representative of their respective populations[18, 19]. The replication of analyses from CPRD in SIDIAP was undertaken to check the generalisability of results identified in the UK to other European countries. Differences between CPRD and SIDIAP are mainly due to difference in the population, since the datasets collect data in the same manner. Scientific approval was obtained for CPRD (protocol number 15\_153R2) and SIDIAP (protocol number 148). Data were extracted and analysed by independent statisticians using an agreed common data structure and shared programming codes.

**Study population**

Our target population was patients with two or more eGFR measurements under 45 ml/min/1.73m2, aged 40 years or older. Patients had to be registered with a practice considered “up to standard” by that database for at least 1 year before their first low eGFR measurement. eGFR estimates were obtained directly from biochemistry data and calculated using the CKD Epidemiology Collaboration formula based on serum creatinine if automated laboratory reporting of eGFR was not available[20].

Patients were excluded if they had used bisphosphonates in the year before their index date (first bisphosphonate use), used non-oral bisphosphonate anti-osteoporotic therapies at any time before their index date, were missing index of multiple deprivation information (social deprivation level in CPRD), or had no follow-up eGFR measurement.

**Study exposure: bisphosphonate use**

Oral bisphosphonate prescriptions (CPRD) and dispensations (SIDIAP) were identified using previously validated lists of prodcodes in CPRD and anatomic therapeutic chemical classification (ATC) codes in SIDIAP. All participants joined the study unexposed to bisphosphonates on their second eGFR measurement under 45 ml/min/1.73m2. Participants could contribute both exposed and unexposed time, as illustrated in Supplement 1. Participants were followed until the end of enrolment in the database (moving out, death, or 10 years), an incident record of the outcome of interest, stopping treatment (6 months), or switching treatment (bisphosphonate users only). A washout period of 6 months plus 30 days from the last prescription or dispensation accounted for carry-over effects. Code lists are provided in <https://github.com/vystrauss/BisCK/tree/master>.

**Outcomes**

The primary outcome was CKD stage worsening, based on follow-up annual eGFR measurements in primary-care records, dialysis, a kidney transplant recorded in CPRD-HES with relevant codes from the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) or fourth version of the OPCS Classification of Interventions and Procedures (OPCS-4), or a record in the renal registry in SIDIAP. CKD stage worsening included a move from stage 3b (eGFR 30-45 ml/min/1.73m2) to stage 4 (eGFR 15-30 ml/min/1.73m2) or 5 (eGFR under 15 ml/min/1.73m2), or from stage 4 to 5.

The secondary outcomes of interest were hospitalisation for acute kidney injury; hospitalisation for, or a primary-care record of, peptic ulcer or gastrointestinal bleeding; and hospitalisation for hypocalcaemia, identified with ICD-10 codes.

**Covariates**

Covariates were identified in a consensus meeting between two clinicians and one epidemiologist using a predefined list of potential confounders identified in the literature. Forty-five covariates were selected, including patient demographics, clinical diagnoses identified with Read codes (CPRD) or ICD-10 (SIDIAP), and previous drug use ascertained using prodcodes (CPRD) or ATC codes (SIDIAP). Covariates are listed in the footnote of Supplement 2.

**Statistical analyses**

A propensity score (PS) was estimated using the 45 covariates with logistic regression. The PS represented the probability of receiving oral bisphosphonates based on the covariates and exact matching on years of follow-up. Missing data for body mass index, smoking category, drinking category (CPRD), and creatinine (SIDIAP) were imputed in ten datasets using multiple imputation by chained equations, assuming data were missing at random. Exposed participants were PS-matched with up to five unexposed participants on a calliper width of 0.2 standard deviations of the logit of the PS, without replacement. The absolute standardised mean difference (ASMD) was used to evaluate balance, with values below 0.1 indicating good balance.

Incidence rates and their 95% confidence intervals (CIs) were reported per 1,000 person-years in the PS-matched and full cohorts. Unadjusted and fully adjusted Cox proportional hazard models were used to calculate hazard ratios (HRs) for each of the outcomes. Fine and Gray sub-HRs were calculated for the PS-matched cohorts to account for any difference in death rate due to PS matching. The proportionality assumption of all models was checked using Schoenfeld Residuals. The proportionality assumption held for all models (data not shown). We combined the results from CPRD and SIDIAP in fixed-effects meta-analyses to produce an overall estimate.

Numbers needed to harm after 3 and 5 years were calculated from Kaplan-Meier curves for the primary outcome. Supplement 3 contains the sample size calculation.

**Additional and sensitivity analyses**

Two pre-defined interactions with bisphosphonate use were tested, gender and history of fracture at any location except the digits, with a cut-off of p<0.1. Stratified Fine and Gray regressions were reported if there was evidence of significant interactions. Medication possession ratios (MPR) were calculated as the number of defined daily doses from the first prescription/dispensation until 30 days after the last record, divided by the number of days within this time window. Fine and Gray models were repeated for MPR quartiles (0 versus <0.83, 0.83-0.97, 0.97-1.05, and >1.05) to test the biological gradient of the Bradford-Hill causality criteria[21].

The effect of potential unmeasured confounding was measured using an array analysis[22] for any significant result in CPRD. The percentage unexposed with the unmeasured confounder was set at 30%, based on unpublished data. The array analysis combined a range of values for the unmeasured variable’s exposed prevalence (30% to 80%) and the association with the study outcome (1.0 to 3.0) to adjust the main (estimated) treatment effect size.

Data were analysed in R version 3.3.2 (CPRD) and 3.5.1 (SIDIAP). Packages used included mice[23], MatchIT[24], survival[25], and survminer[26].

The reporting guidelines of STROBE were followed when writing this paper.

**Funding**

Funding was provided by the National Institute of Health Research Health Technology Assessment project number 14/36/02. The project was partially funded by CIBERFES, Instituto Carlos III, Spain. JP and MJP-S are supported by PI19/00037 (Spanish Ministry of Health ISCIII FIS-FEDER) and RD16/0009/0013 (ISCIII FEDER RedinRen). This work was supported by the NIHR Biomedical Research Centre, Oxford. AJ was supported by the NIHR Biomedical Research Centre at University Hospitals BristolandWestonNHS Foundation Trust and the University of Bristol.

**Role of the funding source**

No funder was directly involved in any aspect of this work. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care**.**

**RESULTS**

We identified 217,405 patients with an eGFR ≤ 45 ml/min/1.73m2 in CPRD, of whom 53,986 patients contributed unexposed time and 2,613 bisphosphonate exposure time. We identified 40,800 unexposed and 1,408 exposed patients in SIDIAP. Figure 1 shows all exclusions. The most common reasons for exclusion were not having two eGFR measurements and not having any follow-up eGFR data available.

[Figure 1]

Across 10 imputed datasets, on average 2,447 bisphosphonate users were matched with 8,931 non-users in CPRD and 1,399 users were matched with 6,547 non-users in SIDIAP. Table 1 reports characteristics after imputation and before and after PS matching.

[Table 1]

Participants were well-matched, including on key covariates such as age, BMI and baseline eGFR, with ASMDs of less than 0.1 for all covariates in the PS in both datasets (Supplement 3), although there were differences in rates (Table 1). In CPRD the average age was 80 with approximately 27% of patients male whilst in SIDIAP the average age was 78 with approximately 23% of patients male.

In the PS-matched cohorts, participants were followed up for a total of 7,287 exposed and 26,731 unexposed person-years in CPRD (median of 3.0 years for both users and non-users) and 3,946 exposed and 20,152 unexposed person-years in SIDIAP (median of 4.4 years for users and 4.8 years for non-users), before censoring at an outcome of interest.

The risk of death differed between users and non-users in only the PS-matched cohort from CPRD (HR [95% CI]: 0.67 [0.62, 0.73]).

CKD stage worsening

In CPRD, 2,572 events occurred, including 229 dialysis or transplant events. The incidence rate of CKD stage worsening was 89.1 (95% CI: 82.1, 96.7) per 1,000 person-years in bisphosphonate users and 85.6 (82.0, 89.5) in non-users (Table 2). Figure 2.1 shows the cumulative incidence of stage worsening and death. The number needed to harm was 40.8 after 3 years and 20.7 after 5 years.

[Table 2]

[Figure 2]

Similar results were found in SIDIAP. There were 2,482 events, with incidence rates of 118.4 per 1,000 person-years in users and 100.0 in non-users. The number needed to harm was 29.4 after 3 years and 28.6 after 5 years.

Combining results from CPRD and SIDIAP gave a PS-matched cohort sub-HR (95% CI) of 1.14 (1.07, 1.23) and a whole cohort HR of 1.18 (1.11, 1.26) (Table 2). Supplement 4 gives the full results of the multiple regression model for CPRD.

In CPRD, significant interactions were identified with history of fracture (p = 0.03) and gender (p = 0.04). Those with a history of fracture were more likely to experience stage worsening (sub-HR [95% CI]: 1.36 [1.08, 1.71]) than those without a history of fracture (1.10 [0.99, 1.22]), although the CIs overlapped. Women were more likely to experience stage change (1.24 [1.11, 1.38]) than men (1.00 [0.83, 1.21]).

Those in the highest MPR quartile ratio category were at highest risk of CKD stage worsening and those with the lowest ratio were at least risk, although the CIs overlapped (Supplement 5).

The array analysis (Figures 3a-b) showed that unmeasured confounding was unlikely to negate the identified risk of HR 1.14 (1.04, 1.26). For the risk identified to be negated, more than 50% of the bisphosphonate users needed to have the confounder, with an HR of 3.0 between the confounder and CKD stage worsening. The presented results would be more than 25% biased. The results would also be negated if more than 80% of the participants had the confounder, with an association (HR) of 1.75 (results 20% biased).

[Figure 3]

Acute kidney injury

The PS-matched CPRD and SIDIAP cohorts contained 482 and 597 acute kidney injury events, respectively. There was no significant difference in the risk of developing an acute kidney injury between bisphosphonate users and non-users, with a combined sub-HR (95% CI) of 0.92 (0.78, 1.08) (Table 2).

No significant interactions were identified in sensitivity analyses. Less than 15% of the participants experienced an acute kidney injury within 10 years (Supplement 6). Participants exposed to bisphosphonates with a MPR between 97% and 105.2% had a lower risk of acute kidney injury than if matched unexposed patients (HR [95% CI]: 0.55 [0.32, 0.94]). However, no dose-response effect was found.

Gastrointestinal events

The rates of gastrointestinal events were 5.5 (4.0, 7.5) per 1,000 patient-years for users and 6.4 (5.5, 7.4) for non-users in the CPRD PS-matched cohort and 1.9 (0.9, 3.5) for users and 1.9 (1.4, 2.5) for non-users in the SIDIAP PS-matched cohort. No difference was found between users and non-users in any of the cohorts (Table 2).

No interactions were identified in sensitivity analyses. More than 95% of participants did not experience a gastrointestinal events within 10 years (Supplement 7).

Hypocalcaemia

Hospitalisation for hypocalcaemia was rare, with only 28 events in the CPRD PS-matched cohort and 7 in the SIDIAP PS-matched cohort. There was no difference in risk in CPRD, with an HR of 0.34 (0.08, 1.43) for the PS-matched cohort. The HR was not calculated for the SIDIAP cohort due to the few events. More than 99% of participants did not experience hypocalcaemia within 10 years (data not shown) in both cohorts.

**DISCUSSION**

**Statement of principal findings**

We used routinely collected data from primary-care practices and hospitals in the UK and Spain and linked renal registry information (Spain only) to assess the safety of bisphosphonate use in patients with stage 3b-5 CKD. Our analyses included nearly 4,000 bisphosphonate users with at least two measurements of eGFR under 45 ml/min/1.73m2, PS-matched to over 15,000 non-users.

Bisphosphonate users had a 14% higher risk of CKD stage progression (including dialysis and transplant) than non-users. Stage progression was a common event, experienced by approximately 1 in 10 patients. In CPRD, the increased risk was equivalent to a number needed to harm of 20: for every 20 patients treated for 5 years, 1 additional patient would progress in CKD stage.

Bisphosphonates, an analogue of pyrophosphate, have been shown, in vivo, not to affect the calcification of certain tissues including the kidney. [27] However, bisphosphonates are eliminated through the kidney by both passive glomerular filtration and active transportation in renal proximal tubular cells as explained by Miller [28]. High doses given in animal models have shown a variety of adverse renal events. However, no bisphosphonate trial has identified an increased risk of CKD progression [29], although most trials were limited to patients with an eGFR > 30. There is anecdotal evidence (case reports and case series) suggesting that bisphosphonates can cause various types of kidney injury [30, 31]. Finally, because of the reduced ability of patients diagnosed with CKD to excrete bisphosphonates, Torregrosa et al [32] have suggested that patients with CKD stage 4 or 5 should have their bisphosphonates reduced to 50% the dose to prevent renal toxicity which would speed up CKD progression.

It has previously been shown that CKD progression occurs later for women than men, potentially explaining the increased risk identified in the interaction analysis for women but not men[33]. The differences identified in the interaction analysis with fracture are potentially an artefact of the data due to a lack of patients with a history of fracture as shown by the overlapping confidence intervals. This interaction should be replicated.

A dose-response relationship was identified between bisphosphonate use and CKD progression in sensitivity analyses. The array analysis showed that the identified result would only be nullified in extreme situations[22].

We found no association between bisphosphonate use and acute kidney injury, gastrointestinal events, or hypocalcaemia.

**Limitations**

This work was undertaken using observational data, whereas previous studies have used data from randomised control trials. However, the strengths of using these different data sources have previously been compared.

Although differences between bisphosphonate users and non-users were minimised with PS matching, differences may have remained. This is particularly true for unidentified confounders not included in the PS. An array analysis of hypothetical unmeasured confounders suggested the results would only be nullified if they were biased more than 20% which is unlikely.

There was potential for exposure misclassification. Although we could confirm whether patients had been prescribed (CPRD) and dispensed (SIDIAP) bisphosphonates, we could not confirm whether they had taken those prescriptions.

There was potential for confounding by indication in the eGFR stage change outcome, as patients with low eGFR who were on bisphosphonates may have had their eGFR measured more frequently.

The reduced risk of death found for bisphosphonate users in CPRD suggested the existence of residual unmeasured confounding. However, no effect on death was identified in SIDIAP, and multiple regressions in the two databases gave similar results. It is therefore unlikely that the reduced risk of death in CPRD substantially affected the results after the cause-specific hazards were calculated. Furthermore, other studies [34] have demonstrated a reduced risk of mortality in bisphosphonate users compared to non-users in the general population, suggesting that any residual confounding will not significantly bias the results. The differential risk of death between databases may be due to the propensity score matching itself. Reasons for this difference are beyond the scope of the study.

There were no data available on injectable bisphosphonates – which are administered in a hospital setting – in the two datasets. Our results are only generalisable to oral bisphosphonates prescribed in primary care, reflecting the individuals included in the two datasets.

The eGFR was calculated using the CKD-EPI formula when estimated eGFR was not available. These measurements have previously been criticised as they may not be accurate in certain patient subgroups. Other measurements for CKD stage, such as the Kidney Disease Improving Global Outcomes classification, could not be used as they rely on general practitioners to collect multiple tests during routine care. Furthermore, unlike the FDA, the EMA bases their advice for the restricted use of bisphosphonates in patients with low kidney function on eGFR instead of creatinine clearance. This may mean there is an overestimation patients with an eGFR <30 ml/min/1.73 m2. However, we would expect the rate of difference in results to be equal between users and non-users*.*

A high proportion of patients (approximately 75%) were female in our study meaning there may be questions about how meaningful results are for Men. This proportion is representative of osteoporosis patients (for which bisphosphonates are the first line treatment). Hence, we can say that these results are representative of a population of bisphosphonate users.

This analysis only investigated first change of eGFR stage instead of sustained eGFR stage change. However, when those with eGFR stage change were assessed for sustained change between calendar years, it was found that 75% of bisphosphonate users and 64% of non-users had sustained eGFR stage change, suggesting that bisphosphates are associated with more permanent damage. Further research is needed into this area, but this remains outside the scope of the original aim of the study.

Finally, an interaction between eGFR starting class and stage change was not undertaken. The reasons for this were two fold, first the opportunity for patients with CKD stage 3b and 4 to experience stage change is much higher than those in CKD stage 5 because patients with CKD stage 5 can only undergo dialysis and transplant to experience a stage change. Second, there were only 45 patients who started with CKD stage 5, meaning this sensitivity analysis would be substantially underpowered and may lead to misleading results.

**Meaning of this study**

As there is little information available on the safety of bisphosphonates in patients with moderate-to-severe CKD, this study makes a significant addition to the body of knowledge. Reassuringly, we found no excess risk for acute kidney injury, gastrointestinal events, or hypocalcaemia with bisphosphonate use. However, these results must be considered alongside the excess risk identified in CPRD and SIDIAP for CKD stage progression. The moderate number needed to harm identified for CPRD suggests that bisphosphonates, which are currently contraindicated or used with caution in patients with an eGFR under 30 ml/min/1.73m2, should continue to be used with caution in this population.

The results of this study support previous findings that bisphosphonate use is not related to acute kidney injuries, gastrointestinal events, or hypocalcaemia [14]. As CKD progression due to bisphosphonate use alone has not previously been researched, comparison with prior studies is difficult. Both datasets are from high-income, predominantly Caucasian settings.

It is the suggestion of the authors that clinicians should carefully consider the risk-benefit of initiating bisphosphonate therapy in patients with an eGFR between 30 and 45. Once started, it would be advisable to monitor renal function and keep evaluating the potential trade off in light of clinical data. Clinicians should follow their local/regional guidelines as to which measure of eGFR they should use. A recent European consensus [35] on the diagnosis and management of osteoporosis in severe CKD provides useful guidance for clinical practice.

**Unanswered questions and future research**

Whilst the results demonstrated an increased risk of CKD stage change with bisphosphonate use, the mechanisms behind this decreasing eGFR are unclear. We investigated a first decrease in CKD stage, rather than changes in the eGFR trajectory over time. We identified an increased risk of CKD stage change in patients with eGFR under 45 ml/min/1.73m2 who use bisphosphonates.We have not yet answered the question “Do bisphosphonates increase the risk of CKD stage decreasing in patients with an eGFR between 45 and 60 ml/min/1.73m2 (CKD stage 3a)?”

**Conclusion**

In a PS-matched analysis of two electronic primary-care datasets linked to hospital records, an increased rate of CKD progression was identified for bisphosphonate users with CKD stage 3b-5, compared with non-users. Bisphosphonate use was not associated with a higher rate of acute kidney injuries, gastrointestinal events, or hypocalcaemia.

**ACKNOWLEDGEMENTS**

This study was approved by the CPRD Independent Scientific Advisory Committee (protocol number 15\_ 53R2A). The interpretation and conclusions contained in this study are those of the authors alone. We acknowledge two public and patient involvement representatives (Denisse Abbott from the National Kidney Federation and Fizz Thompson from the National Osteoporosis Society) and English language editing by Dr Jennifer A. de Beyer of the Centre for Statistics in Medicine, University of Oxford.

**Registrations:**

Scientific approval was obtained for use of CPRD (ISAC 15\_153R2) and SIDIAP data (148). The study protocol was registered in the EU PAS Register for pharmaco-epidemiological studies [ref 10029].

**REFERENCES**

1. Kerr, M., *Chronic Kidney Diesease in England: The Human and Financial Cost*, N.H.S. England, Editor. 2017.

2. Otero, A., et al., *Prevalence of chronic renal disease in Spain: results of the EPIRCE study.* Nefrologia, 2010. **30**(1): p. 78-86.

3. Pan, B.-L. and S.-S. Loke, *Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome.* PloS one, 2018. **13**(1): p. e0190985-e0190985.

4. Nickolas, T.L., D.J. McMahon, and E. Shane, *Relationship between moderate to severe kidney disease and hip fracture in the United States.* J Am Soc Nephrol, 2006. **17**(11): p. 3223-32.

5. Ensrud, K.E., et al., *Renal function and risk of hip and vertebral fractures in older women.* Arch Intern Med, 2007. **167**(2): p. 133-9.

6. Dooley, A.C., N.S. Weiss, and B. Kestenbaum, *Increased risk of hip fracture among men with CKD.* Am J Kidney Dis, 2008. **51**(1): p. 38-44.

7. Alem, A.M., et al., *Increased risk of hip fracture among patients with end-stage renal disease.* Kidney Int, 2000. **58**(1): p. 396-9.

8. National Institue for Heatlth and Care Excellence, *Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)*. 2008.

9. National Institue for Heatlth and Care Excellence, *Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)*. 2008.

10. National Institue for Heatlth and Care Excellence, *Chronic kidney disease in adults: assessment and management (CG182)*. 2014.

11. *Summary of Product Characteristics - Bonviva*, Roche Products Limited, Editor. 2011.

12. *Summary of Product Characteristics - Actonel 30mg*, Warner Chilcott UK, Editor. 2011.

13. *Summary of Product Characteristics - Fosamax Onces Weekly.*, Merck Sharp and Dohme, Editor. 2012.

14. Wilson, L.M., et al., *Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.* Ann Intern Med, 2017. **166**(9): p. 649-658.

15. *KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).* Kidney Int Suppl (2011), 2017. **7**(1): p. 1-59.

16. Herrett, E., et al., *Data Resource Profile: Clinical Practice Research Datalink (CPRD).* Int J Epidemiol, 2015. **44**(3): p. 827-36.

17. SIDIAP. *SIDIAP Information System for Research in Primary Care*. 2014 [cited 2019 23/08].

18. Herrett, E., et al., *Validation and validity of diagnoses in the General Practice Research Database: a systematic review.* Br J Clin Pharmacol, 2010. **69**(1): p. 4-14.

19. Garcia-Gil Mdel, M., et al., *Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP).* Inform Prim Care, 2011. **19**(3): p. 135-45.

20. Levey, A.S., et al., *A new equation to estimate glomerular filtration rate.* Ann Intern Med, 2009. **150**(9): p. 604-12.

21. Hill, A.B., *THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?* Proc R Soc Med, 1965. **58**: p. 295-300.

22. Schneeweiss, S., *Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.* Pharmacoepidemiol Drug Saf, 2006. **15**(5): p. 291-303.

23. van Buuren, S. and K. Groothuis-Oudshoorn, *mice: Multivariate Imputation by Chained Equations* R. Journal of Statistical Software, 2011. **45**(3): p. 1-67.

24. Daniel E. Ho, et al., *MatchIt: Nonparametric Preprocessing for Parametric Causal Inference.* Journal of Statistical Software, 2011. **42**(8): p. 1-28.

25. Therneau, T., *A Package for Survival Analysis in S*. 2015.

26. Alboukadel Kassambara and Marcin Kosinski, *survminer: Drawing Survival Curves using 'ggplot2'*. 2018: R.

27. Fleisch, H., et al., *The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo.* Calcified Tissue Research, 1968. **2**(1): p. 10-10.

28. Miller, P.D., *The kidney and bisphosphonates.* Bone, 2011. **49**(1): p. 77-81.

29. Miller, P.D., et al., *Renal safety in patients treated with bisphosphonates for osteoporosis: A review.* Journal of Bone and Mineral Research, 2013. **28**(10): p. 2049-2059.

30. Markowitz, G.S., et al., *Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.* J Am Soc Nephrol, 2001. **12**(6): p. 1164-72.

31. Barri, Y.M., et al., *Podocyte injury associated glomerulopathies induced by pamidronate.* Kidney International, 2004. **65**(2): p. 634-641.

32. Torregrosa, J.V. and A.M. Ramos, *Use of bisphosphonates in chronic kidney disease.* Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2010. **30**(3): p. 288-296.

33. Cobo, G., et al., *Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis.* Clin Sci (Lond), 2016. **130**(14): p. 1147-63.

34. Bliuc, D., et al., *Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis.* Journal of Bone and Mineral Research, 2019. **34**(11): p. 2001-2011.

35. Evenepoel, P., et al., *European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D.* Nephrol Dial Transplant, 2020.

**Figure titles and legends:**

**Figure 1:**

Title: Flow diagrams for patient exclusions in CPRD (left) and SIDIAP (right) identifying when and why patients were excluded from each dataset

Notes: \*= patients contribute both unexposed and exposed time. See Supplement 1 for full explanation. eGFR = estimated glomerular filtration rate in ml/min/1.73m2, IMD = index of multiple deprivation

**Figure 2:**

Title: Survival plots for stage change with renal replacement therapy showing the (a) cumulative incidence of the outcome in CPRD data, (b) cumulative incidence of competing risk (death) in CPRD data, (c) cumulative incidence of the outcome and competing risk in CPRD.

Note: These figures are calculated as part of a competing risk model using Fine and Gray survival analysis.

**Figure 3:**

Title: Array of unmeasured confounding based on a HR of 1.14 and an unexposed incident of the outcome of 30%: a) adjusted hazard ratio (HR); b) percentage bias.

Note: In figure a, darker grey regions show situations when the result would be nullified since the combination of percentage of exposed patients with the confounder and high risk of association induce a large enough amount of bias to affect the results. In figure b, lighter grey regions suggest more bias and therefore are less likely to be realistic situations. The same position of figure a and b can be taken together to identify the amount of bias and corresponding effect to the HR.

**Tables:**

**Table 1: Baseline characteristics before and after matching for CPRD and SIDIAP**

|  | **CPRD** | **SIDIAP** |
| --- | --- | --- |
|  | **Before matching,** **after imputation** | **After matching** | **Before matching,** **after imputation** | **After matching** |
| **Category** | **Non-BP** | **BP** | **Non-BP** | **BP** | **Non-BP** | **BP** | **Non-BP** | **BP** |
| Number | 53,986 | 2,613 | 8,931 | 2,447 | 40,800 | 1,408 | 6,547 | 1,399 |
| Age (mean, SD) | 77.6 (9.8) | 80.6 (8.8) | 80.3 (9.1) | 80.4 (8.8) | 78.9 (10.0) | 78.8 (7.7) | 78.7 (10.0) | 78.8 (7.7) |
| Gender (male) (n, %) | 23,280 (43.1) | 595 (22.8) | 2669 (29.9) | 584 (23.9) | 15,366 (37.7) | 314 (22.3) | 1,609 (24.6) | 314 (22.4) |
| Socio-economic deprivation (n, %) |  |  |  |  |  |  |  |  |
| 1 - least deprived | 11,949 (22.1) | 637 (24.4) | 2127 (23.8) | 587 (24.0) | 5,325 (13.1) | 211 (15.0) | 935 (14.3) | 210 (15.0) |
| 2 | 12,649 (23.4) | 620 (23.7) | 2089 (23.4) | 585 (23.9) | 5,318 (13.0) | 194 (13.8) | 944 (14.4) | 193 (13.8) |
| 3 | 11,539 (21.4) | 550 (21.0) | 1881 (21.1) | 517 (21.1) | 5,342 (13.1) | 170 (12.1) | 816 (12.5) | 169 (12.1) |
| 4 | 10,771 (20.0) | 480 (18.4) | 1654 (18.5) | 452 (18.5) | 4,967 (12.2) | 161 (11.4) | 734 (11.2) | 161 (11.5) |
| 5 - most deprived | 7,078 (13.1) | 326 (12.5) | 1180 (13.2) | 306 (12.5) | 4,789 (11.7) | 181 (12.9) | 792 (12.1) | 178 (12.7) |
| Urban (deprivation level undefined) | N/A | N/A | N/A | N/A | 4,879 (12.0) | 201 (14,3) | 934 (14.3) | 200 (14.3) |
| Rural |  |  |  |  | 10,180 (25.0) | 290 (20.6) | 1392 (21.3) | 288 (20.6) |
| BMI (mean, SD)a | 27.6 (5.5) | 26.7 (5.2) | 26.9 (5.4) | 26.8 (5.3) | 29.1 (5.2) | 29.1 (5.1) | 29.1 (5.4) | 29.1 (5.1) |
| Smoking category (n, %)b |  |  |  |  |  |  |  |  |
| No | 28,093 (52.0) | 1,423 (54.5) | 4784 (53.6) | 1329 (54.3) | 30,904 (75.7) | 1,159 (82.3) | 5,324 (81.3) | 1,150 (82.2) |
| Ex | 19,910 (36.9) | 966 (37.0) | 3295 (36.9) | 906 (37.0) | 6,515 (16.0) | 158 (11.2) | 776 (11.9) | 158 (11.3) |
| Yes | 5,983 (11.1) | 224 (8.6) | 852 (9.5) | 212 (8.7) | 3,381 (8.3) | 91 (6.5) | 447 (6.8) | 91 (6.5) |
| Drinking category (n, %)c |  |  |  |  |  |  |  |  |
| No | 14,621 (27.1) | 781 (29.9) | 2663 (29.8) | 734 (30.0) | NA | NA | NA | NA |
| Ex | 2,117 (3.9) | 126 (4.8) | 400 (4.5) | 118 (4.8) | NA | NA | NA | NA |
| Yes | 37,248 (69.0) | 1706 (65.3) | 5868 (65.7) | 1595 (65.2) | NA | NA | NA | NA |
| eGFR category (ml/min/1.73 m2) (n, %) |  |  |  |  |  |  |  |  |
| 0 - 4.9 | 67 (0.1) | 1 (0.0) | 5 (0.1) | 1 (0.0) | 74 (0.2) | 1 (0.1) | 8 (0.1) | 1 (0.1) |
| 5 - 9.9 | 362 (0.7) | 16 (0.6) | 60 (0.7) | 16 (0.7) | 388 (1.0) | 7 (0.5) | 51 (0.8) | 7 (0.5) |
| 10 - 14.9 | 616 (1.1) | 29 (1.1) | 116 (1.3) | 29 (1.2) | 785 (1.9) | 15 (1.1) | 114 (1.7) | 15 (1.1) |
| 15 - 19.9 | 1,278 (2.4) | 81 (3.1) | 263 (2.9) | 73 (3.0) | 1,568 (3.8) | 37 (2.6) | 207 (3.2) | 37 (2.6) |
| 20 - 24.9 | 2,541 (4.7) | 164 (6.3) | 537 (6.0) | 149 (6.1) | 2,814 (6.9) | 99 (7.0) | 425 (6.5) | 98 (7.0) |
| 25 - 29.9 | 4,665 (8.6) | 327 (12.5) | 996 (11.2) | 299 (12.2) | 4,983 (12.2) | 172 (12.2) | 759 (11.6) | 172 (12.3) |
| 30 - 34.9 | 8,417 (15.6) | 542 (20.7) | 1709 (19.1) | 498 (20.4) | 7,741 (19.0) | 272 (19.3) | 1,126 (17.2) | 269 (19.2) |
| 35 - 39.9 | 14,415 (26.7) | 704 (26.9) | 2378 (26.6) | 657 (26.8) | 10,830 (26.5) | 399 (28.3) | 1,807 (27.6) | 397 (28.4) |
| 40 - 44.9 | 21,625 (40.1) | 749 (28.7) | 2867 (32.1) | 725 (29.6) | 11,617 (28.5) | 406 (28.8) | 2,050 (31.3) | 403 (28.8) |
| Number of hospital visits (n, %) |  |  |  |  |  |  |  |  |
| 0 | 33,367 (61.8) | 1,022 (39.1) | 4066 (45.5) | 988 (40.4) | NA | NA | NA | NA |
| 1 | 10,968 (20.3) | 737 (28.2) | 2368 (26.5) | 683 (27.9) | NA | NA | NA | NA |
| 2 | 4,971 (9.2) | 399 (15.3) | 1170 (13.1) | 367 (15.0) | NA | NA | NA | NA |
| 3 – 5 | 3,876 (7.2) | 371 (14.2) | 1078 (12.1) | 340 (13.9) | NA | NA | NA | NA |
| 6+ | 804 (1.5) | 84 (3.2) | 249 (2.8) | 69 (2.8) | NA | NA | NA | NA |
| Charlson score (n, %) |  |  |  |  |  |  |  |  |
| 0 | 30,485 (56.5) | 682 (26.1) | 3107 (34.8) | 671 (27.4) | 7,392 (18.1) | 313 (22.2) | 1,339 (20.5) | 308 (22.0) |
| 1 | 7,723 (14.3) | 364 (13.9) | 1366 (15.3) | 350 (14.3) | 7,605 (18.6) | 297 (21.1) | 1,330 (20.3) | 293 (20.9) |
| 2 | 7,719 (14.3) | 604 (23.1) | 1905 (21.3) | 565 (23.1) | 9,604 (23.5) | 318 (22.6) | 1,501 (22.9) | 318 (22.7) |
| 3 – 5 | 6,468 (12.0) | 746 (28.5) | 2001 (22.4) | 666 (27.2) | 14,375 (35.2) | 450 (32.0) | 2,212 (33.8) | 450 (32.2) |
| 6+ | 1,591 (2.9) | 217 (8.3) | 552 (6.2) | 195 (8.0) | 1,824 (4.5) | 30 (2.13) | 165 (2.5) | 30 (2.1) |
| Rheumatoid arthritis (n, %) | 532 (1.0) | 148 (5.7) | 171 (1.9) | 136 (5.6) | 478 (1.2) | 49 (3.48) | 206 (3.2) | 49 (3.5) |
| Varices (n, %) | 3,323 (6.2) | 316 (12.1) | 886 (9.9) | 281 (11.5) | 4,674 (11.5) | 206 (14.6) | 933 (14.3) | 204 (14.6) |
| DVT (n, %) | 1,895 (3.5) | 113 (4.3) | 388 (4.3) | 108 (4.4) | 3 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Type 2 diabetes (n, %) | 6,172 (11.4) | 404 (15.5) | 1304 (14.6) | 371 (15.2) | 14,524 (35.6) | 473 (33.6) | 2,202 (33.6) | 470 (33.6) |
| Dementia (n, %) | 944 (1.7) | 79 (3.0) | 263 (2.9) | 74 (3.0) | 2,968 (7.27) | 97 (6.9) | 472 (7.2) | 97 (6.9) |
| CKD (n, %) | 8,245 (15.3) | 1,381 (52.9) | 3479 (39.0) | 1225 (50.1) | 17,649 (43.3) | 810 (57.5) | 3,568 (54.5) | 801 (57.3) |
| Cerebral vascular disease (n, %) | 4,193 (7.8) | 320 (12.2) | 976 (10.9) | 299 (12.2) | 5,890 (14.4) | 196 (13.9) | 9,20 (14.1) | 192 (13.7) |
| Peripheral vascular disease (n, %) | 1246 (2.3) | 88 (3.4) | 266 (3.0) | 80 (3.3) | 2,848 (6.98) | 89 (6.3) |  |  |
| Hypertension (n, %) | 23,630 (43.8) | 1,518 (58.1) | 4628 (51.8) | 1391 (56.8) | 33,622 (82.4) | 1,182 (83.9) | 5,495 (83.9) | 1176 (84.1) |
|  Hyperlipidaemia (n, %) | 5,788 (10.7) | 459 (17.6) | 1289 (14.4) | 415 (17.0) | 17,206 (42.2) | 660 (46.9) | 2,934 (44.8) | 657 (47.0) |
| Liver disease (n, %) | 224 (0.4) | 32 (1.2) | 73 (0.8) | 28 (1.1) | 1,528 (3.75) | 62 (4.4) | 277 (4.2) | 61 (4.4) |
| Peptic ulcer (n, %) | 816 (1.5) | 65 (2.5) | 187 (2.1) | 58 (2.4) | 1,620 (3.97) | 63 (4.5) | 186 (2.8) | 63 (4.5) |
| Osteomalacia / rickets (n, %) | 15 (0.0) | 2 (0.1) | 5 (0.1) | 2 (0.1) | NA | NA | NA | NA |
| Cancer (n, %) | 5,415 (10.0) | 454 (17.4) | 1374 (15.4) | 416 (17.0) | 5,790 (14.2) | 212 (15.1) | 956 (14.6) | 209 (14.9) |
| Hip fracture (n, %) | 440 (0.8) | 33 (1.3) | 125 (1.4) | 32 (1.3) | 1,175 (2.9) | 97 (6.9) | 406 (6.2) | 93 (6.7) |
| Non-hip fracture (n, %) | 2,088 (3.9) | 577 (22.1) | 1070 (12.0) | 482 (19.7) | 2,981 (7.3) | 264 (18.8) | 1,102 (16.8) | 257 (18.4) |
| Number of prescriptions (n, %) |  |  |  |  |  |  |  |  |
| 0 | 1,527 (2.9) | 4 (0.2) | 72 (0.9) | 4 (0.2) | 501 (5.2) | 0 (0.0) | 45 (0.7) | 0 (0.0) |
| 1 – 3 | 6,880 (13.3) | 61 (2.5) | 360 (4.3) | 61 (2.7) | 1,869 (4.6) | 10 (0.7) | 208 (3.2) | 10 (0.7) |
| 4 – 6 | 12,453 (24.0) | 230 (9.4) | 1104 (13.3) | 226 (9.9) | 8,252 (20.2) | 102 (7.2) | 1,049 (16.0) | 102 (7.3) |
| 7 – 9 | 12,408 (23.9) | 468 (19.2) | 1763 (21.2) | 451 (19.7) | 13,982 (34.3) | 336 (23.9) | 2,165 (33.1) | 336 (24.0) |
| 10 – 12 | 9,019 (17.4) | 548 (22.5) | 1906 (22.9) | 519 (22.7) | 11,025 (27.0) | 486 (34.5) | 1,894 (28.9) | 481 (34.4) |
| 13+ | 9,524 (18.4) | 1,129 (46.3) | 3125 (37.5) | 1026 (44.9) | 5,171 (12.7) | 474 (33.7) | 1,186 (18.1) | 470 (33.6) |
| Hormone replacement therapy (n, %) | 2979 (5.5) | 244 (9.3) | 714 (8.0) | 228 (9.3) | 857 (2.1) | 53 (3.8) | 257 (3.7) | 51 (3.9) |
| Contraceptive (n, %) | 38 (0.1) | 1 (0.0) | 5 (0.1) | 1 (0.0) | 7 (0.0) | 2 (0.1) | 4 (0.1) | 2 (0.1) |
| Calcium supplements (n, %) | 3,996 (7.4) | 782 (29.9) | 1818 (20.4) | 680 (27.8) | 485 (1.2) | 25 (1.8) | 95 (1.4) | 24 (1.7) |
| Bisphosphonate use more than 1 year before index date (n, %) | 996 (1.8) | 136 (5.2) | 486 (5.4) | 122 (5.0) | 1,831 (4.5) | 99 (7.0) | 450 (6.9) | 98 (7.0) |
| Steroids (n, %) | 9,194 (17.0) | 1,311 (50.2) | 3509 (39.3) | 1179 (48.2) | 3,996 (9.8) | 301 (21.4) | 1,263 (19.3) | 296 (21.2) |
| Anticoagulants (n, %) | 7,078 (13.1) | 486 (18.6) | 1567 (17.5) | 455 (18.6) | 22,876 (56.1) | 832 (59.1) | 3,818 (58.3) | 824 (58.9) |
| Heparin (n, %) | 432 (0.8) | 61 (2.3) | 160 (1.8) | 51 (2.1) | 2,224 (5.5) | 119 (8.5) | 521 (8.0) | 116 (8.3) |
| Aromatase inhibitors (n, %) | 265 (0.5) | 58 (2.2) | 122 (1.4) | 45 (1.8) | 330 (0.8) | 20 (1.4) | 91 (1.4) | 19 (1.4) |
| Non-steroidal anti-inflammatories (n, %) | 30,095 (55.7) | 1,873 (71.7) | 5862 (65.6) | 1737 (71.0) | 15,187 (37.2) | 714 (50.7) | 3,116 (47.6) | 707 (50.5) |
| Proton pump inhibitors (n, %) | 19,596 (36.3) | 1,593 (61.0) | 4795 (53.7) | 1465 (59.9) | 26,547 (65.1) | 1,114 (79.1) | 5,018 (76.6) | 1,105 (79.0) |
| Anxiols / sedatives / hypnotics (n, %) | 10,488 (19.4) | 726 (27.8) | 2429 (27.2) | 668 (27.3) | NA | NA | NA | NA |
| Antidepressants (n, %) | 14,578 (27.0) | 1,118 (42.8) | 3386 (37.9) | 1032 (42.2) | 7,268 (17.8) | 349 (24.8) | 1,530 (23.4) | 346 (24.7) |
| Statins (n, %) | 21,548 (39.9) | 1,402 (53.7) | 4368 (48.9) | 1293 (52.8) | 17,835 (43.7) | 644 (45.7) | 2,949 (45.0) | 642 (45.9) |
| Calcium channel blockers (n, %) | 23,668 (43.8) | 1,507 (57.7) | 4683 (52.4) | 1392 (56.9) | 370 (0.9) | 6 (0.4) | 32 (0.5) | 6 (0.4) |
| ACE inhibitors (n, %) | 32,246 (59.7) | 1,907 (73.0) | 6142 (68.8) | 1773 (72.5) | 18774 (46.0) | 572 (40.6) | 2,714 (41.5)720 (11.0) | 568 (40.6)163 (11.7) |
| Antiepileptics (n, %) | 2,251 (4.2) | 207 (7.9) | 631 (7.1) | 192 (7.8) | 3,466 (8.50) | 166 (11.8) |
| Diuretics (n, %) | 38,403 (71.1) | 2,164 (82.8) | 7139 (79.9) | 2023 (82.7) | NA | NA | NA | NA |
| Beta blockers (n, %) | 25,175 (46.6) | 1,395 (53.4) | 4461 (49.9) | 1302 (53.2) | 10,625 (26.0) | 379 (26.9) | 1,782 (27.2) | 375 (26.8) |
| Digoxin (n, %) | 5,839 (10.8) | 319 (12.2) | 1152 (12.9) | 310 (12.7) | 2,946 (7.2) | 99 (7.0) | 476 (7.3) | 97 (7.0) |
| Antihypertensives (n, %) | 8,608 (15.9) | 588 (22.5) | 1770 (19.8) | 548 (22.4) | NA | NA | NA | NA |
| Antiarrythmics (n, %) | 7,010 (13.0) | 447 (17.1) | 1418 (15.9) | 417 (17.0) | 2,386 (5.9) | 84 (6.0) | 436 (6.7) | 84 (6.0) |
| Insulin (n, %) | 2,359 (4.4) | 127 (4.9) | 421 (4.7) | 120 (4.9) | 5,417 (13.3) | 197 (14.0) | 871 (13.3) | 196 (14.0) |
| a – BMI missing in 468 (17.9%) exposed and 17,915 (33.2%) unexposed patients in CPRD and 677 (47.2%) exposed and 20,402 (49.1%) unexposed patients in SIDIAP before imputation.b – Smoking category missing in 238 (9.1%) exposed and 13,239 (24.5%) unexposed patients in CPRD and 294 (20.5%) exposed and 7,124 (17.1%) unexposed patients in SIDIAP before imputation.c – Drinking category missing in 665 (25.5%) exposed and 21,581 (40.0%) unexposed patients in CPRD before imputation. |
| ACE = angiotensin-converting enzyme, BMI = body mass index, BP = bisphosphonate, CKD = chronic kidney disease, CPRD = Clinical Practice Research Datalink, DVT = deep vein thrombosis, eGRF = estimated glomerular filtration rate, SIDIAP = Information System for the Development of Research in Primary Care, NA = Not available in this dataset |

**Table 2: Numbers of events, incidence rates, and hazard ratios for all analyses.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | CPRD | SIDIAP |  |
| BP | Non-BP | BP | Non-BP | Combined |
| Chronic kidney disease progression | Unmatched n. events | 614 | 15,411 | 471 | 13,462 |  |
| Unmatched incidence rates | 90.8 (83.9, 98.3) | 73.3 (72.1, 74.4) | 119.0 (108.5,130.2) | 104.7 (102.9,106.5) |  |
| Unadjusted HR | **1.25 (1.15, 1.36)** | **1.13 (1.03, 1.23)** | **1.19 (1.12, 1.27)** |
| Fully adjusted HR | **1.18 (1.08, 1.29)** | **1.19 (1.08, 1.31)** | **1.18 (1.11, 1.26)** |
| PS-matched n. events | 576 | 1,996 | 467 | 2015 |  |
| PS-matched incidence rates | 89.1 (82.1, 96.7) | 85.6 (82.0, 89.5) | 118.4 (107.9,129.6) | 100.0 (95.7,104.5) |  |
| PS-matched sub-HR | **1.14 (1.04, 1.26)** | **1.15 (1.04, 1.27)** | **1.14 (1.07, 1.23)** |
| Acute kidney injury | Unmatched n. events | 83 | 2,739 | 101 | 3,203 |  |
| Unmatched incidence rates | 11.7 (9.5, 14.6) | 11.2 (10.8, 11.6) | 19.8 (16.1, 24.0) | 19.6 (18.9, 20.3) |  |
| Unadjusted HR | 1.11 (0.89, 1.38) | 1.01 (0.83, 1.23) | 1.05 (0.91, 1.22) |
| Fully adjusted HR | 0.84 (0.66, 1.05) | 1.07 (0.88, 1.31) | 0.97 (0.83, 1.12) |
| PS-matched n. events | 80 | 402 | 99 | 498 |  |
| PS-matched incidence rates | 15.2 (13.8, 16.8) | 12.0 (9.7, 14.9) | 19.5 (15.9, 23.8) | 19.6 (17.9, 21.4) |  |
| PS-matched sub-HR | 0.86 (0.67, 1.09) | 0.97 (0.78, 1.21) | 0.92 (0.78, 1.08) |
| Gastrointestinal event | Unmatched n. events | 38 | 1,294 | 10 | 338 |  |
| Unmatched incidence rates | 5.3 (3.9, 7.3) | 5.3 (5.0, 5.6) | 1.9 (0.9, 3.5) | 2.0 (1.8, 2.2) |  |
| Unadjusted HR | 0.97 (0.71, 1.35) | 0.97 (0.52, 1.82) | 0.97 (0.73, 1.29) |
| Fully adjusted HR | 1.00 (0.71, 1.41) | 1.18 (0.62, 2.22) | 1.04 (0.77, 1.40) |
| PS-matched n. events | 37 | 160 | 10 | 49 |  |
| PS-matched incidence rates | 5.5 (4.0, 7.5) | 6.4 (5.5, 7.4) | 1.9 (0.9, 3.5) | 1.9 (1.4, 2.5) |  |
| PS-matched sub-HR | 0.96 (0.67, 1.39) | 0.99 (0.50, 1.96) | 0.97 (0.70, 1.33) |
| Hypocalcaemia | Unmatched n. events | 2 | 155 | 1 | 14 |  |
| Unmatched incidence rates | 0.3 (0.1, 1.1) | 0.6 (0.5, 0.7) | 0.2 (0.0, 1.1) | 0.1 (0.0, 0.1) |  |
| Unadjusted HR | 0.45 (0.11, 1.82) | NA | NA |
| Fully adjusted HR | 0.28 (0.07, 1.17) | NA | NA |
| PS-matched n. events | 2 | 26 | 1 | 6 |  |
| PS-matched incidence rates | 0.3 (0.1, 1.2) | 1.1 (0.8, 1.6) | 0.2 (0, 1.1) | 0.2 (0.1, 0.5) |  |
| PS-matched sub-HR | 0.34 (0.08, 1.43) | NA | NA |
| BP = bisphosphonate, CPRD = Clinical Practice Research Datalink, HR = hazard ratio, PS = propensity score, SIDIAP = Information System for the Development of Research in Primary Care, NA = analysis not undertaken due to lack of events. |